Format

Send to

Choose Destination
Drugs. 2018 May;78(7):781-785. doi: 10.1007/s40265-018-0907-5.

Ibalizumab: First Global Approval.

Author information

1
Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand. dru@adis.com.

Abstract

TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)-a humanised IgG4 monoclonal antibody-as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS. This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment.

PMID:
29675744
PMCID:
PMC5988774
DOI:
10.1007/s40265-018-0907-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center